Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies
This article was originally published in The Pink Sheet Daily
An FDA alert about a cluster of Streptococcus endophthalmitis infections in Florida suggests concerns about aseptic conditions in pharmacies that repackage Avastin for off-label intravitreal use.
You may also be interested in...
Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.
With safety in mind, NICE is to publish product summaries on the off-label use of specific medicines, but stresses that this is not meant to encourage the practice.
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.